|Day's Range||4.31 - 4.38|
|52 Week Range||3.95 - 8.35|
|PE Ratio (TTM)||12.15|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
Nuvo Pharmaceuticals™ Inc. Announces Topline Results from European Ankle Sprain Study with Pennsaid® 2%
MISSISSAUGA, ON, May 15, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today reported topline results from its multi-centre, randomized, placebo-controlled, double-blind, parallel group trial in patients, with grade I or II ankle sprains (the Trial) and in particular reported that the Trial had failed to meet its primary endpoint.
MISSISSAUGA, ON, May 15, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (NRI.TO), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that the United States District Court for the District of New Jersey has upheld the validity of Horizon Pharma plc's (Horizon) (HZNP) U.S. patent covering Pennsaid® (diclofenac sodium topical solution) 2% w/w (Pennsaid 2%), which Actavis Laboratories UT, Inc. (Actavis) has admitted that its proposed generic version of Pennsaid 2% would infringe. Nuvo earns revenue by selling commercial bottles and physician samples of Pennsaid 2% to Horizon under an exclusive manufacturing and supply agreement that extends to 2029. On July 6, 2015, Horizon filed a patent infringement lawsuit in District Court against Actavis related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration (FDA) to market a generic version of Pennsaid 2% in the U.S. The lawsuit claims infringement of Horizon's U.S. Patent No. 9,066,913 ('913 patent) titled "Diclofenac Topical Formulation," which covers Pennsaid 2%. Horizon has advised Nuvo that the District Court's decision was made based on the validity of Horizon's '913 patent for Pennsaid 2% and that the Court's judgement will prevent Actavis from launching a generic version of Pennsaid 2% in the United States.